U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description

Menthyl lactate is derived from menthol, a compound that comes from peppermint oil, or is made synthetically. Menthol has a natural cooling effect, which makes it useful as a topical analgesic to treat skin irritation, pain, itching or sunburn. Despite its cooling benefits, menthol can be a skin irritant. Like menthol, menthyl lactate is cooling, but it causes less skin irritation than menthol. Menthyl lactate also has a refreshing, minty taste. For this reason, some manufacturers use it as a flavoring ingredient. The compound is recommended for use as a flavor in concentrations of 0.005% to 0.2% and in cosmetic and other external products in concentrations ranging from 0.2% to 2.0%. Menthyl lactate is a known compound available e.g. from Haarmann & Reimer GmbH (Germany) under the name FRESCOLAT, Type ML.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
37.8 µM [IC50]
300.0 µM [IC50]
30.0 µM [EC50]
68.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BENGAY
Palliative
BENGAY
Palliative
Unknown
Palliative
VICKS VAPORUB
Primary
VICKS VAPORUB
Primary
CVS ANTI ITCH
Palliative
VICKS VAPORUB
Palliative
Unknown
Primary
FRESCOLAT ML

Cmax

ValueDoseCo-administeredAnalytePopulation
32.89 ng/mL
80 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
31.6 ng/mL
160 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
48 ng/mL
320 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
5617.46 ng/mL
80 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
9882.69 ng/mL
160 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
17601.81 ng/mL
320 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
45.46 ng × h/mL
80 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
52.64 ng × h/mL
160 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
109.34 ng × h/mL
320 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
9676.67 ng × h/mL
80 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
15639.85 ng × h/mL
160 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
32115.5 ng × h/mL
320 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.0306 h
80 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
1.7739 h
160 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
1.222 h
320 mg single, intragastric
LEVOMENTHOL plasma
Homo sapiens
7.8072 h
80 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
5.5689 h
160 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens
5.8693 h
320 mg single, intragastric
MENTHOL GLUCURONIDE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
15.3%
LEVOMENTHOL plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
2.5% of RACEMENTHOL apply to affected area not more than 3 to 4 times daily
Route of Administration: Topical
In Vitro Use Guide
After the d-menthol exposure (2.0 g in the 600 ml culture medium), the dry weight of the Microcystis aeruginosa FACHB-905 cells gradually decreased; the decrease in the dry weight after 5d exposure was 29, 12, and 2 mgL(-1) when the initial cell densities were 1.4×10(7), 1.2×10(6), and 2.9×10(5) cellmL(-1), respectively.
One of these components may be present:
Definition References
(2)